About Antios Therapeutics
Antios Therapeutics is a company based in Atlanta (United States) founded in 2018 by Abel De La Rosa and Idean Marvasty. It operates as a HealthTech. Antios Therapeutics has raised $200.4 million across 4 funding rounds from investors including EPIQ, RA Capital and GordonMD Global Investments. Antios Therapeutics offers products and services including ATI-2173 and 4th Generation CAM Program. Antios Therapeutics operates in a competitive market with competitors including SSI Strategy, Fusion Antibodies, Health Decisions, August Research and Phastar, among others.
- Headquarter Atlanta, United States
- Founders Abel De La Rosa, Idean Marvasty
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Antios Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$200.4 M (USD)
in 4 rounds
-
Latest Funding Round
$75 M (USD), Series B
Nov 03, 2021
-
Investors
EPIQ
& 21 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Antios Therapeutics
Antios Therapeutics offers a comprehensive portfolio of products and services, including ATI-2173 and 4th Generation CAM Program.
ATI-2173 is developed as HBV polymerase inhibitor nucleotide.
CAM program is designed for targeted HBV virus clearance.
People of Antios Therapeutics
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Antios Therapeutics
Antios Therapeutics has successfully raised a total of $200.4M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $75 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Antios Therapeutics
Antios Therapeutics has secured backing from 22 investors, including venture fund and institutional investors. Prominent investors backing the company include EPIQ, RA Capital and GordonMD Global Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment management services are provided in the biopharmaceutical sector.
|
Locked | Locked | Locked | |
|
Diversified asset management services are offered by EPIQ.
|
Locked | Locked | Locked | |
|
Private equity investments are directed toward the healthcare sector.
|
Locked | Locked | Locked |
Investor details for Antios Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Antios Therapeutics
Investment portfolio details for Antios Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Antios Therapeutics
Detailed financials for Antios Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Antios Therapeutics Comparisons
Peer comparison for Antios Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Antios Therapeutics
Antios Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SSI Strategy, Fusion Antibodies, Health Decisions, August Research and Phastar, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmacovigilance and medical affairs services are offered for drug development.
|
|
| Locked | Locked | Locked |
Company offering a range of services in antibody production, development, characterization and optimization right from discovery to commercialization
|
|
| Locked | Locked | Locked |
CRO focused on clinical trial services for data management, monitoring and biostatistics
|
|
| Locked | Locked | Locked |
Clinical trial services are offered in Central and Eastern Europe.
|
|
| Locked | Locked | Locked |
Statistical consulting and data management for clinical trials are offered.
|
|
| Locked | Locked | Locked |
Regulatory and pharmacovigilance support is provided for product lifecycles.
|
Detailed competitors of Antios Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Antios Therapeutics
Complete news archive for Antios Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Antios Therapeutics
Antios Therapeutics was founded in 2018.
Antios Therapeutics is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.
Abel De La Rosa is the current CEO of Antios Therapeutics. They have also founded this company.
Antios Therapeutics is a funded company, having raised a total of $200.4M across 4 funding rounds to date.
Antios Therapeutics is engaged in the development of innovative therapies aimed at treating and potentially curing hepatitis B virus (HBV) and other viral diseases. The company is known for developing ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), which is combined with nucleoside analogues to inhibit HBV replication. Additionally, a 4th generation capsid assembly modulator (CAM) program is being advanced to support immune system clearance of HBV. Their work spans clinical trials and research presentations, contributing to advancements in antiviral treatments within the healthcare sector.
Antios Therapeutics's top competitors include SSI Strategy, Fusion Antibodies and ProductLife Group.
Antios Therapeutics offers ATI-2173 and 4th Generation CAM Program.
Antios Therapeutics has 22 investors. Key investors include EPIQ, RA Capital, GordonMD Global Investments, CAM Capital, and Avego.